Anatara Lifesciences Ltd (ASX:ANR)

Australia flag Australia · Delayed Price · Currency is AUD
0.0110
0.00 (0.00%)
Mar 6, 2026, 3:18 PM AEST
-71.79%
Market Cap 3.48M
Revenue (ttm) 623.76K
Net Income (ttm) -1.31M
Shares Out 315.95M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 697,338
Average Volume 823,909
Open 0.0090
Previous Close 0.0110
Day's Range 0.0090 - 0.0110
52-Week Range 0.0040 - 0.0200
Beta 0.62
RSI 47.41
Earnings Date Feb 23, 2026

About Anatara Lifesciences

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight redu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol ANR
Full Company Profile

Financial Performance

In fiscal year 2025, Anatara Lifesciences's revenue was 969,456, an increase of 50.53% compared to the previous year's 644,026. Losses were -1.95 million, 34.7% more than in 2024.

Financial Statements

News

There is no news available yet.